Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD) -- Ignore unavailable to you. Want to Upgrade?

To: atticus4paws who wrote (59)	12/10/2004 2:03:28 PM
From: scaram(o)uche	Respond to of 588

Yup. Lasts until 12/05, according to the S-1. Anybody have newer news??

To: atticus4paws who wrote (59)	12/10/2004 2:11:13 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 588

from the 2003 Arqule 10-K..... ACADIA Pharmaceuticals. On December 18, 2000, ArQule and ACADIA Pharmaceuticals entered into a drug discovery collaboration. Under the agreement, ACADIA combined its functional genomics platform with ArQule's Parallel Track Drug Discovery Program to discover novel small-molecule drug candidates directed at individual G-protein coupled receptor (GPCR) targets. The companies shared intellectual property resulting from the collaboration. Under the agreement, the companies will share any revenues resulting from the commercialization of joint drug discovery programs. In addition to these joint drug discovery programs, each company will receive exclusive rights to certain compounds that the companies have decided not to develop in a joint drug discovery program, subject to a royalty payment to the other party. In July 2002, we decided to cease our efforts on this collaboration in order to focus on our internal drug discovery programs.